Read Summary

Abstract

This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.

Footnotes

  • Please Note

    The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way.

    © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

  • Disclosures for the Non–Small Cell Lung Cancer Panel

    At the beginning of each NCCN Guidelines panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.

    Individual disclosures for the NCCN Non–Small Cell Lung Cancer Panel members can be found on page 535. (The most recent version of these guidelines and accompanying disclosures are available on the NCCN Web site at NCCN.org.)

    These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

  • NCCN Non–Small Cell Lung Cancer Panel Members

    *David S. Ettinger, MD/Chair†

    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    *Douglas E. Wood, MD, FRCSEd/Vice Chair¶

    Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

    Dara L. Aisner, MD, PhD≠

    University of Colorado Cancer Center

    Wallace Akerley, MD†

    Huntsman Cancer Institute at the University of Utah

    Jessica Bauman, MD‡

    Fox Chase Cancer Center

    Lucian R. Chirieac, MD≠

    Dana-Farber/Brigham and Women’s Cancer Center

    Thomas A. D’Amico, MD¶

    Duke Cancer Institute

    Malcolm M. DeCamp, MD¶

    Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Thomas J. Dilling, MD, MS§

    Moffitt Cancer Center

    Michael Dobelbower, MD, PhD§

    University of Alabama at Birmingham Comprehensive Cancer Center

    Robert C. Doebele, MD, PhD†

    University of Colorado Cancer Center

    Ramaswamy Govindan, MD†

    Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

    Matthew A. Gubens, MD, MS†

    UCSF Helen Diller Family Comprehensive Cancer Center

    Mark Hennon, MD¶

    Roswell Park Cancer Institute

    Leora Horn, MD, MSc, FRCPC†

    Vanderbilt-Ingram Cancer Center

    Ritsuko Komaki, MD§

    The University of Texas MD Anderson Cancer Center

    Rudy P. Lackner, MD¶

    Fred & Pamela Buffett Cancer Center

    Michael Lanuti, MD¶

    Massachusetts General Hospital Cancer Center

    Ticiana A. Leal, MD†

    University of Wisconsin Carbone Cancer Center

    Leah J. Leisch, MDÞ

    University of Alabama at Birmingham Comprehensive Cancer Center

    Rogerio Lilenbaum, MD†

    Yale Cancer Center/Smilow Cancer Hospital

    Jules Lin, MD¶

    University of Michigan Comprehensive Cancer Center

    Billy W. Loo Jr, MD, PhD§

    Stanford Cancer Institute

    Renato Martins, MD, MPH†

    Fred Hutchinson Cancer Research Center/Seattle Cancer Care

    Alliance Gregory A. Otterson, MD†

    The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

    Karen Reckamp, MD, MS†‡

    City of Hope Comprehensive Cancer Center

    Gregory J. Riely, MD, PhD†Þ

    Memorial Sloan Kettering Cancer Center

    Steven E. Schild, MD§

    Mayo Clinic Cancer Center

    Theresa A. Shapiro, MD, PhD¥

    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    James Stevenson, MD†

    Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

    Scott J. Swanson, MD¶

    Dana-Farber/Brigham and Women’s Cancer Center

    Kurt Tauer, MD†

    St. Jude Children’s Research Hospital/University of Tennessee Health Science Center

    Stephen C. Yang, MD¶

    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    NCCN Staff: Kristina Gregory, RN, MSN, OCN, and Miranda Hughes, PhD

    KEY:

    *Discussion Section Writing Committee

    Specialties: †Medical Oncology; ¶Surgery/Surgical Oncology; §Radiation Oncology/Radiotherapy; ≠Pathology; ‡Hematology/Hematology Oncology; фDiagnostic/Interventional Radiology; ¥Patient Advocate; ÞInternal Medicine

Print Friendly, PDF & Email